PENG Block Versus Epidural Block for Postoperative Analgesia After Total Hip Arthroplasty

November 11, 2026 updated by: Mohammad Shafiqul Islam, Bangladesh Medical University

Evaluation of Pericapsular Nerve Group (PENG) Block and Epidural Block for Postoperative Analgesia Following Total Hip Arthroplasty: a Comparative Study

This study aims to compare the effectiveness of ultrasound-guided Pericapsular Nerve Group (PENG) block and epidural block for postoperative analgesia in patients undergoing elective unilateral total hip arthroplasty. A total of 62 eligible patients will be randomly allocated into two groups: Group A will receive epidural block, and Group B will receive PENG block. Postoperative pain scores, opioid consumption, time to first rescue analgesia, motor blockade, adverse effects, and time to mobilization will be assessed to compare the analgesic efficacy and recovery outcomes of the two techniques.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Postoperative pain management is an important component of recovery following total hip arthroplasty. Epidural analgesia is an established regional anesthesia technique, whereas ultrasound-guided Pericapsular Nerve Group (PENG) block is a newer technique intended to provide targeted analgesia to the hip joint.

This single-blind, randomized controlled trial will compare these two techniques in 62 patients undergoing elective unilateral total hip arthroplasty at Bangladesh Medical University, Dhaka, Bangladesh.

Participants will be randomly assigned in a 1:1 ratio to receive either an epidural block or a PENG block. Both groups will receive standardized postoperative multimodal analgesia. Pain intensity will be assessed using the Numeric Rating Scale (NRS) at 0, 2, 4, 6, 12 and 24 hours after surgery. Additional outcomes will include total opioid consumption, time to first rescue analgesia, motor blockade, adverse effects, and time to mobilization.

The findings will help compare the analgesic effectiveness and postoperative recovery associated with these two regional anesthesia techniques.

Study Type

Interventional

Enrollment (Estimated)

62

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Dhaka, Bangladesh, 1000
        • Bangladesh Medical University
        • Contact:
        • Principal Investigator:
          • Suma Rani Paul
        • Sub-Investigator:
          • Saiful Mahmud Tusher, FCPS

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 64 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients aged 18- 64 years, either sex
  • Gender: Male and Female
  • ASA physical status: I, II, or III
  • Patients undergoing elective unilateral total hip arthroplasty
  • Written informed consent obtained

Exclusion Criteria:

  • Patient refusal to participate
  • Known allergy to local anesthetics
  • Infection at block site
  • Coagulopathy (INR >1.5, Platelet <100,000/mm³)
  • Neurological deficits in operated limb
  • Chronic opioid use

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Group A

Participants will receive an epidural block before spinal anaesthesia using an 18G Tuohy needle at L2-L3 or L3-L4, followed by a test dose with 3 mL of 2% lidocaine with adrenaline and 15-20 mL of 0.25% bupivacaine.

Participants will receive an epidural block before spinal anaesthesia using an 18G Tuohy needle at L2-L3 or L3-L4, followed by a test dose and 15-20 mL of 0.25% bupivacaine.

Experimental: Group B

Participants will receive an ultrasound-guided PENG block in the supine position before spinal anaesthesia, using a 22-gauge needle and 20 mL of 0.25% bupivacaine.

Participants will receive an ultrasound-guided Pericapsular Nerve Group Block (PENG) block before induction in the supine position, using a 22G needle and 20 mL of 0.25% bupivacaine.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative pain score at rest and on movement using the Numeric Rating Scale (NRS)
Time Frame: At the recovery room- 0, 2, 4, 6, 12 and 24 hours after surgery

Pain intensity will be assessed using a 10-cm Numeric Rating Scale (NRS). The scale ranges from 0 to 10 cm, where 0 cm indicates no pain and 10 cm indicates the worst imaginable pain. Higher scores indicate greater pain intensity.

At the recovery room- 0, 2, 4, 6, 12 and 24 hours after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to First Rescue Analgesia
Time Frame: Within 24 hours after surgery

Time from completion of surgery to the first administration of rescue analgesia (intravenous morphine 0.05 mg/kg when the Numeric Rating Scale pain score is 4 or higher). The time will be recorded in minutes.

Within 24 hours after surgery
Total Opioid Consumption
Time Frame: Time Frame: First 24 hours after surgery.

Total amount of intravenous morphine administered as rescue analgesia to each participant during the first 24 hours after surgery, measured in milligrams (mg).T

Time Frame: First 24 hours after surgery.
Postoperative Motor Blockade
Time Frame: At the recovery room- 0, 2, 6 hours after surgery

Motor blockade will be assessed using the Modified Bromage Scale, ranging from 0 to 3. A score of 0 indicates no motor block, while a score of 3 indicates complete motor block with inability to move the hip, knee, and ankle. Higher scores indicate greater motor blockade.

At the recovery room- 0, 2, 6 hours after surgery
Postoperative Adverse Effects
Time Frame: First 24 hours after surgery

Description:

The occurrence of postoperative adverse effects, including hypotension, nausea, vomiting, and urinary retention, will be recorded for each participant. Each adverse effect will be documented as present or absent.

First 24 hours after surgery
Time to First Mobilization
Time Frame: Within 24 hours after surgery

Time from surgery completion until the participant first stands or walks. The time will be recorded in minutes.

Within 24 hours after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

May 31, 2027

Study Completion (Estimated)

May 31, 2027

Study Registration Dates

First Submitted

November 11, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • BMU/2026/20/000013

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.